MALCOLM JAN 4

What Happened
Jan Malcolm, a director of United Therapeutics (UTHR), sold 50 shares on February 3, 2026. The shares were disposed at $474.23 per share for a reported total of $23,712. The filing indicates the sale was executed pursuant to a Rule 10b5-1 trading plan, which typically reflects a pre-scheduled trade rather than ad hoc insider trading.

Key Details

• Transaction date: 2026-02-03
• Type: Sale (code S) reported as "Open market or private sale"
• Price: $474.23 per share; Shares sold: 50; Reported proceeds: $23,712
• Footnote: Sale executed pursuant to a Rule 10b5-1 plan entered on Sep 11, 2025
• Shares owned after transaction: Not specified in the disclosed summary
• Filing timeliness: Reported on the same date (no late filing indicated in this report)

Context
A 10b5-1 trading plan allows insiders to set up scheduled trades in advance and is commonly used to avoid questions about trading on nonpublic information. Sales under such plans are often routine (e.g., diversification or liquidity needs) and do not necessarily signal a change in the director’s view of the company.